
Diffuse idiopathic skeletal hyperostosis (DISH) has traditionally been regarded as an age-related radiographic disorder characterized by flowing spinal ossification. Advances in epidemiology, imaging, and pathobiology have progressively challenged this restricted view, suggesting a broader systemic disorder of pathological bone formation involving axial and peripheral entheses. This narrative review examines the evolution of the DISH disease concept, integrating historical descriptions and diagnostic criteria with contemporary evidence from epidemiological, imaging, clinical, genetic, metabolic, and mechanistic studies. This review emphasizes developments that have changed our understanding of disease definition, heterogeneity, and pathogenesis. The Resnick and Niwayama criteria established a reproducible radiographic framework for DISH but predominantly identify established spinal disease and incompletely capture earlier or extraspinal manifestations. Modern computed tomography and magnetic resonance imaging have broadened recognition of the anatomical spectrum and highlighted overlap with degenerative and inflammatory spinal disorders. Epidemiological and mechanistic studies increasingly associate DISH with metabolic susceptibility, genetic factors, mechanical loading, and dysregulated osteogenic responses at the enthesis. These observations support a transition from viewing DISH as an isolated spinal radiographic abnormality toward a systemic osteoproliferative entheseal disorder with heterogeneous clinical and imaging phenotypes. Nevertheless, validated biomarkers, standardized criteria for early disease, and disease-modifying therapies remain lacking. The conceptual evolution of DISH has important implications for diagnosis, phenotyping, and future research. Integration of standardized imaging with clinical, metabolic, genetic, and molecular characterization may enable earlier recognition, biologically informed phenotyping, and ultimately more individualized approaches to disease management.
Introduction: Bimekizumab, a humanised monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, was efficacious and well tolerated to 52 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in the global phase 3 multicentre study BE MOBILE 1. In this pre-specified analysis, we examine in more detail the efficacy and safety of bimekizumab in the Chinese subpopulation of patients with nr-axSpA from BE MOBILE 1. Methods: BE MOBILE 1 comprised a 16-week double-blind, placebo-controlled period and 36-week maintenance period. Patients with nr-axSpA were randomised to receive subcutaneous bimekizumab 160 mg every 4 weeks or placebo to week 16; thereafter, all patients received bimekizumab. Here we report efficacy and safety outcomes to week 52 for the Chinese subpopulation. No formal statistical comparisons were made; results should be interpreted as nominal. Results: Overall, 36/274 patients in BE MOBILE 1 were enrolled in China (bimekizumab-randomised 18; placebo-randomised 18); 32 completed week 52. A greater proportion of bimekizumab- vs placebo-randomised patients achieved Assessment of SpondyloArthritis international Society (ASAS) >= 40% response (38.9% vs 22.2%), ASAS partial remission (33.3% vs 11.1%), and Axial Spondyloarthritis Disease Activity Score < 2.1 (77.7% vs 49.7%) at week 16. By week 52, improvements were comparable between bimekizumab-randomised and placebo-randomised patients who had switched to bimekizumab. Similar trends were observed for objective signs of inflammation, spinal pain, physical function, health-related quality of life, and peripheral manifestations. To week 52, treatment-emergent adverse events (TEAEs) occurred in 33 bimekizumab-treated patients (91.7%), with upper respiratory tract infection the most frequent (10 patients [27.8%]). Four patients (11.1%) had serious TEAEs; four had fungal infections (11.1%; all Tinea). No patients experienced adjudicated inflammatory bowel disease or uveitis. Conclusions: In patients with nr-axSpA from China, bimekizumab showed rapid and sustained efficacy improvements to week 52 and was well tolerated, consistent with the global patient population.
Randomised controlled trials have demonstrated the efficacy and safety of ixekizumab as a treatment for active psoriatic arthritis (PsA), and real-world evidence on long-term persistence and effectiveness is emerging. This study aimed to characterise ixekizumab use in the Italian routine clinical setting and provide insights into its persistence and effectiveness, complementing real-world evidence from single-country cohorts and multinational studies. This descriptive, multicentre, retrospective study was conducted in Italy in adult patients with PsA who received a first prescription of ixekizumab after January 2021 and had a minimum of three subsequent evaluations. The primary objective was to describe treatment persistence at week 104. Secondary objectives aimed to describe patients’ demographic and clinical characteristics and evaluate treatment persistence and effectiveness at weeks 12, 24, 52 and 104. A total of 204 patients, of whom 88 (43.1
Understanding comparative effectiveness of different biologic therapies in patients with inadequate response to a prior tumor necrosis factor inhibitor (TNFi) may guide treatment decisions. This real-world analysis compared the clinical effectiveness of upadacitinib versus other advanced treatments (ATs), including TNFi, interleukin (IL)-6 inhibitors, and T cell co-stimulation modulators, in patients with rheumatoid arthritis (RA) who previously received a TNFi. This retrospective cohort study used data from the OM1® RA Registry (OM1, Inc.; Boston, MA, USA). Patients with RA (≥ 18 years) treated with upadacitinib or other ATs who previously received a TNFi and had high disease activity (Clinical Disease Activity Index [CDAI] > 22) and both a tender joint count and swollen joint count of ≥ 6 at baseline were included. The outcome of interest was achievement of CDAI low disease activity (LDA)/remission at 12 months. Descriptive statistics were reported for proportion of patients who achieved CDAI LDA/remission at 12 months. Multivariable analyses using generalized estimating equation compared CDAI LDA/remission rates for upadacitinib versus IL-6 inhibitors, T cell co-stimulation modulator, and TNFi. A total of 378 patients were included in the analysis: upadacitinib (N = 73), IL-6 inhibitors (N = 64), T cell co-stimulation modulator (N = 76), or a different TNFi (N = 165). Descriptive statistics showed a greater proportion of patients receiving upadacitinib achieved CDAI LDA/remission at 12 months (43.8
Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy and an acceptable safety profile in rheumatoid arthritis (RA) clinical trials, but real-world (RW) long-term data are limited. This sub-analysis of UPHOLD evaluated the long-term effectiveness and safety of UPA over 2 years in adults with moderate-to-severe RA in Germany, Austria, and Switzerland. UPHOLD (NCT04497597) is an international, observational cohort study of adults with moderate-to-severe RA in whom the treating physician decided to initiate treatment with UPA 15 mg once daily prior to study enrollment. Effectiveness was assessed using disease activity measures, including the Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP), as well as patient-reported outcomes (PROs). Endpoints were analyzed by modified nonresponder imputation (mNRI) and as observed (AO). All treatment-emergent adverse events (TEAEs), including selected TEAEs of interest, are reported as exposure-adjusted event rates (events per 100 patient-years [E/100PY]). Of the 268 patients who were enrolled, 262 received at least one UPA dose and 150 (56.0